Stakeholder Opinions: Respiratory viral infections - Respiratory syncytial virus, parainfluenza virus and human metapneumovirus as promising new targets
- Published: April 2010
Although the market is already crowded, antiviral agents that can treat diseases such as HIV and hepatitis C virus (HCV) can still expect success. This potential for success is only one of the reasons that 122 companies are actively involved in clinical development of 139 antiviral agents despite the plethora of available agents. Given the need for therapies that can deal with mutating viruses that render current therapies ineffective and for therapies that can treat the side effects that plague patients on long-term antiviral therapy (among other unmet needs), the antivirals market is still an attractive market for drug developers despite various obstacles that are challenging market growth.
Questions Answered in this Report:
- The antivirals market has grown steadily since 2004 and, excepting a less robust period from 2009 to 2010, is expected to continue this steady growth. What forces and trends are driving this growth? What situations will impact sales growth from 2009 to 2010?
- Although a multitude of effective therapies are available to treat indications such as HIV and HCV, unmet needs are still driving significant clinical development in the antivirals pipeline. What are the various unmet needs in HIV, HCV, and other indications? How many antivirals are in development for HIV and HCV, and how can these therapies be classified?
- Both current and emerging market-leading companies will drive the growth of the antivirals market. Which companies are the current market leaders, and which companies are projected to be the market leaders in 2015? Which companies are attempting to establish, grow, or protect their position in this market? Which indications and drug classes will drive most of the growth?
- The antivirals pipeline: Number of agents in development; disease focus; NMEs versus reformulations; formulations by disease; drug targets; small-molecule drugs versus biologics; phase analysis; development by company type; number of agents by phase; number of agents by disease; profiles of GlaxoSmithKline, Pfizer, Viiv Healthcare, and Gilead Sciences.
- Historical and projected antiviral sales: 2004-2015 sales; leading drug classes; current and projected market-leading companies; key patent expiries impacting antiviral sales; R&D spend of market-leading companies.
- Market opportunities/drivers: Oral HCV therapies; drugs to treat mutated HIV viruses and patients who develop long-term side effects from current therapies; antivirals with increased efficacy; better tests to identify mutated viruses and diagnose patients.
- Market constraints: Lack of a “universal” antiviral to treat multiple viral infections; generics.
- Markets covered: United States, rest of world.
- Primary research: Insight from a survey of 100 U.S. board-certified infectious disease specialists.
- Data-rich content: 27 tables and figures that detail our pipeline and market findings.
Key Terms for this Report:
Antivirals, Antivirals market, Antivirals pipeline, Antivirals sales forecast, HCV, Hepatitis C, HIV, Influenza, NRTI, NNRTI, Nucleoside analogue, Protease inhibitor, RSV, Viral resistance, Viral mutation SHOW LESS READ MORE >
The Antivirals Pipeline
GlaxoSmithKline and Pfizer
Opportunities in the Antivirals Pipeline
Oral Therapies: The Holy Grail of HCV Therapy
HIV: A Saturated Market, but Still Room for New Therapies
Emerging Markets: An Attractive Antiviral Launching Pad
Market Statistics and Market Outlook
Market Drivers and Constraints
1. Descriptions of Select Infectious Diseases Treated with Antivirals
2. Common Antiviral Drug Classes to Treat Infectious Diseases
3. GlaxoSmithKline, Pfi zer, and Viiv Healthcare’s Antivirals Pipeline
4. Gilead Sciences’ Antivirals Pipeline
5. 2008 Worldwide Sales of Leading Antivirals
6. 2008 Market-Leading Companies, by Antiviral Sales
7. First Major Patent Expiries of Key Antiviral Drugs, 2009-2015
8. 2015 Market-Leading Companies, by Antiviral Sales
9. 2015 Worldwide Sales of Leading Antivirals
1. Antivirals Pipeline, by Disease
2. Survey Question: In Your Opinion, Which Viral Diseases Are the Subject of the Most Innovative Ongoing Research?
3. Antivirals Pipeline: NMEs Versus Reformulations
4. Antivirals Pipeline, by Formulation
5. Antivirals Pipeline, by Target
6. Antivirals Pipeline, by Development Phase
7. Antivirals Pipeline, Small-Molecule Drugs Versus Biologics
8. Antivirals Pipeline, by Company
9. Leading Antivirals Pipelines, Number of Agents by Phase
10. Leading Antivirals Pipelines, Number of Agents by Indication
11. Antivirals Pipeline, Development Activity by Company Size
12. GlaxoSmithKline Antiviral Franchise Sales, 2008 and 2015
13. Gilead Sciences Antiviral Franchise Sales, 2008 and 2015
14. Worldwide Antivirals Market Growth, 2004-2015
15. Antivirals Market Growth, by Region, 2004-2015
16. Worldwide Sales of Antiviral Drug Classes, 2008 and 2015
17. Survey Question: Is Developing Different Antiviral Delivery and Dosing Modalities an Important Area of Research?
18. Survey Question: What Do You See as the Greatest Challenges in Developing Better Antiviral Drugs?
- Abbott Laboratories
- Astellas Pharma
- BioChem Solutions
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Gilead Sciences
- Idenix Pharmaceuticals
- Japan Tobacco
- Johnson & Johnson
- Merck & Co.
- Mitsubishi Tanabe Pharma
- Pfi zer
- Three Rivers Pharmaceuticals
- Valeant Pharmaceuticals
- Vertex Pharmaceuticals
- Viiv Healthcare
|Electronic (PDF)||The report will be emailed to you. The report is sent in PDF format.||This is a single user license, allowing one specific user access to the product.|
|Enterprisewide||The report will be emailed to you. The report is sent in PDF format.||This is an enterprise license, allowing all employees within your organisation access to the product.|